AZN Relative Valuation
AZN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AZN is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for AZN's competitors is 4.03, providing a benchmark for relative valuation. AstraZeneca PLC Corp (AZN) exhibits a P/S ratio of 3.62, which is -10.17% above the industry average. Given its robust revenue growth of 7.17%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is AstraZeneca PLC (AZN) currently overvalued or undervalued?
What is AstraZeneca PLC (AZN) fair value?
How does AZN's valuation metrics compare to the industry average?
What is the current P/B ratio for AstraZeneca PLC (AZN) as of May 19 2025?
What is the current FCF Yield for AstraZeneca PLC (AZN) as of May 19 2025?
What is the current Forward P/E ratio for AstraZeneca PLC (AZN) as of May 19 2025?